Highly Sensitive Method Detects Malaria Parasites
|
By LabMedica International staff writers Posted on 18 Mar 2015 |

Image: A gametocyte of Plasmodium falciparum in a thin blood smear and also seen are ring-form trophozoites and a red blood cell exhibiting basophilic stippling (Photo courtesy of Dr. Mae Melvin).
A large proportion of asymptomatic malaria infections can only be identified by surveillance with molecular methods, yet these infections also contribute to onward transmission to mosquitoes.
New molecular assays that take advantage of genes with multiple copies in the parasite genome have been developed that can detect malaria parasites in human blood at very low levels and might be helpful in the campaign to eradicate malaria.
An international team of scientists led by those at the Swiss Tropical and Public Health Institute (Basel, Switzerland) compared three methods to detect malaria parasites in 498 samples randomly selected from a malaria survey in Tanzania: light microscopy, the current standard molecular assay, and the new assays. Two quantitative polymerase chain reaction (qPCR) assays were developed for ultra-sensitive detection of Plasmodium falciparum, targeting the high-copy telomere-associated repetitive element 2 (TARE-2, ~250 copies/genome) and the var gene acidic terminal sequence (varATS, 59 copies/genome).
Parasites were detected in 25% of samples by light microscopy, in 50% by the standard assay, and in 58% by the new assays. Compared to the new assays, the current molecular standard assay failed to identify 16% of infections, and at least 40% of those contained parasite gametocytes, the parasite stage that is transmitted when mosquitoes bite an infected person. Standard PCR is widely considered a molecular gold standard of malaria diagnosis complementing light microscopy, the traditional gold standard, yet these results suggest that this notion requires revision.
The new assays detect only the most common malaria parasite, P. falciparum, and while they can use very small blood samples collected in the field, the analysis itself needs to be done in a biomedical laboratory. Nonetheless, because low-density infections without disease symptoms are expected to become increasingly common as countries improve malaria control, ultra-sensitive tools such as these will likely be critical for malaria surveillance and for monitoring the progress of malaria control and elimination programs. The study was published on March 3, 2015, in the journal Public Library of Science Medicine.
Related Links:
Swiss Tropical and Public Health Institute
New molecular assays that take advantage of genes with multiple copies in the parasite genome have been developed that can detect malaria parasites in human blood at very low levels and might be helpful in the campaign to eradicate malaria.
An international team of scientists led by those at the Swiss Tropical and Public Health Institute (Basel, Switzerland) compared three methods to detect malaria parasites in 498 samples randomly selected from a malaria survey in Tanzania: light microscopy, the current standard molecular assay, and the new assays. Two quantitative polymerase chain reaction (qPCR) assays were developed for ultra-sensitive detection of Plasmodium falciparum, targeting the high-copy telomere-associated repetitive element 2 (TARE-2, ~250 copies/genome) and the var gene acidic terminal sequence (varATS, 59 copies/genome).
Parasites were detected in 25% of samples by light microscopy, in 50% by the standard assay, and in 58% by the new assays. Compared to the new assays, the current molecular standard assay failed to identify 16% of infections, and at least 40% of those contained parasite gametocytes, the parasite stage that is transmitted when mosquitoes bite an infected person. Standard PCR is widely considered a molecular gold standard of malaria diagnosis complementing light microscopy, the traditional gold standard, yet these results suggest that this notion requires revision.
The new assays detect only the most common malaria parasite, P. falciparum, and while they can use very small blood samples collected in the field, the analysis itself needs to be done in a biomedical laboratory. Nonetheless, because low-density infections without disease symptoms are expected to become increasingly common as countries improve malaria control, ultra-sensitive tools such as these will likely be critical for malaria surveillance and for monitoring the progress of malaria control and elimination programs. The study was published on March 3, 2015, in the journal Public Library of Science Medicine.
Related Links:
Swiss Tropical and Public Health Institute
Latest Microbiology News
- 15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
- High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
- Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
- Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
- Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
- New Diagnostic Method Confirms Sepsis Infections Earlier
- New Markers Could Predict Risk of Severe Chlamydia Infection
- Portable Spectroscopy Rapidly and Noninvasively Detects Bacterial Species in Vaginal Fluid
- CRISPR-Based Saliva Test Detects Tuberculosis Directly from Sputum
- Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People
- Saliva Test Detects Implant-Related Microbial Risks
- New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance
- Early Detection of Gut Microbiota Metabolite Linked to Atherosclerosis Could Revolutionize Diagnosis
- Viral Load Tests Can Help Predict Mpox Severity
- Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
- Credit Card-Sized Test Boosts TB Detection in HIV Hotspots
Channels
Clinical Chemistry
view channel
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read more
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read moreMolecular Diagnostics
view channel
Hidden Blood Biomarkers to Revolutionize Diagnosis of Diabetic Kidney Disease
Diabetic kidney disease often develops silently, and many patients are diagnosed only after irreversible damage has occurred. Late diagnosis frequently leads to complications affecting the kidneys, heart,... Read more
Genetic Testing Trifecta Predicts Risk of Sudden Cardiac Death and Arrhythmia
Arrhythmias such as atrial fibrillation and sudden cardiac death can develop with few early symptoms, exposing patients to serious complications before treatment begins. Existing genetic tests capture... Read moreHematology
view channel
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read moreImmunology
view channel
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read more
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read morePathology
view channel
Simple Optical Microscopy Method Reveals Hidden Structures in Remarkable Detail
Understanding how microscopic fibers are organized in human tissues is key to revealing how organs function and how diseases disrupt them. However, these fiber networks have remained difficult to visualize... Read more
Hydrogel-Based Technology Isolates Extracellular Vesicles for Early Disease Diagnosis
Isolating extracellular vesicles (EVs) from biological fluids is essential for early diagnosis, therapeutic development, and precision medicine. However, traditional EV-isolation methods rely on ultra... Read moreTechnology
view channel
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read moreIndustry
view channel
Roche and Freenome Collaborate to Develop Cancer Screening Tests
Roche (Basel, Switzerland) and Freenome (Brisbane, CA, USA have entered into a strategic collaboration to commercialize Freenome's cancer screening technology in international markets.... Read more








